Therapeutics that inhibit JAK-STAT pathways are an important focus of research, with a growing body of literature demonstrating that they are safe and efficacious for use in several inflammatory skin conditions, including AD [44]. This evidence concerns the gene SOAT1 and Alzheimer disease.